InnoCare Pharma (09969) reported net profit attributable to shareholders of approximately RMB 656 million for the first three quarters, turning profitable year-on-year.

Zhitong Finance APP news, InnoCare Pharma (09969) announced its performance for the first three quarters of 2026. The company's total operating revenue was RMB 2.099 billion, an increase of 88.21% compared with the same period last year, of which pharmaceutical sales revenue was RMB 1.449 billion, an increase of 41.47% compared with the same period last year. The main reasons for the growth in operating revenue were the continued volume expansion of the core product orelabrutinib, the new sales contributions from tafasitamab and zurletrectinib, and the completion of subsequent milestone deliveries under the company's licensing agreement with Zenas BioPharma, Inc. Net profit attributable to shareholders of the listed company was approximately RMB 656 million, turning from loss to profit year-on-year.